Our Vision
Innovate Renal Therapeutics and provide the best solutions to renal patients
Our Mission
To become a prominent player helping patients fight kidney diseases with our deep knowledge, strong expertise and passion in product discovery and development
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund was founded in Shanghai in early 2018, as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures. Supported by numerous renowned institutional investors specialized in the biopharmaceutical industry, Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund’s pipeline comprises both small-molecule and biologic assets.
Kidney disease is defined as an abnormality of kidney structure or function, which can occur abruptly, and either resolve or become chronic. Chronic Kidney Disease (CKD) is a general term for heterogeneous disorders with variable clinical presentation, in part related to cause, severity and the rate of progression. Chronic kidney disease (CKD) is a condition that poses a growing threat to public health worldwide and has seen its incidence steadily rising in recent years. In China, the latest epidemiology data show that the prevalence of CKD in the adult population is as high as 10.8%, which amounts to a total patient population of 120 million with over one million renal patients at the terminal stage. Meanwhile, the diagnosis rate of CKD in China is just 12.5%, thus suggests enormous unmet patient need for diagnosis and treatment. The goal for the management of CKD is to halt or slow the rate of the progressive loss of the kidney function before they enter the end stage kidney failure, as well as to treat the complications reducing the morbidity and mortality when they enter the end stage kidney failure. The current standard of care for CKD management remains inadequate, the residual cardio-renal risk is still very high, and there is a huge unmet need for the new medication.
Alebund is fully dedicated to providing high quality comprehensive solutions to the renal disease patients for the long-term, with our deep knowledge and expertise in all the areas necessary for Renal Medicines: Research. Development, CMC, Regulatory and Commercialization. Alebund appreciates its employees, collaborators and partners with respect and consideration understanding needs and obligations as it is building an extensive and durable network globally.